Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Brain met outcomes similar for NSCLC, breast cancer patients
Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Key clinical point: Breast cancer patients presented with larger and more numerous brain metastases compared with non–small-cell lung cancer patients, but after brain-directed therapy, there were no differences in outcomes between groups.
Major finding: Median survival was 1.45 years for breast cancer patients and 1.09 for NSCLC patients.
Study details: A retrospective analysis of 349 patients with breast cancer and 659 patients with NSCLC treated between 2000 and 2015 at Dana-Farber/Brigham and Women’s Cancer Center.
Disclosures: The authors reported no conflicts of interest.
Source: Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.